Form 4: MIRA CEO's Stock Options Repriced to $1.38

MIRA Pharmaceuticals' CEO, Erez Aminov, had 300,000 stock options repriced to an exercise price of $1.38, aligning with the recent closing stock price.

Summary

• Erez Aminov, Chief Executive Officer and Director of MIRA Pharmaceuticals, Inc., reported changes in beneficial ownership of derivative securities.
• Two tranches of stock options, totaling 300,000 shares, were repriced by the company's board of directors.
• The first tranche of 150,000 options, originally issued on April 28, 2023, had its exercise price reduced from $5.00 to $1.38.
• The second tranche of 150,000 options, originally issued on August 17, 2023, had its exercise price reduced from $6.50 to $1.38.
• The new exercise price of $1.38 is equal to the closing price of MIRA's common stock on September 15, 2025.
• All other terms of the options remain unchanged, and both tranches are fully vested.

Sentiment

Score: 3

Explanation: The repricing of executive stock options, while potentially re-incentivizing management, generally reflects significant past stock underperformance and can be viewed negatively by shareholders regarding corporate governance and dilution.

Positives

• The repricing of options could re-incentivize the CEO by making the options 'in-the-money' or closer to it, potentially aligning management's interests with shareholders if the stock price recovers.

Negatives

• Option repricing often indicates a significant decline in the company's stock price since the original grant dates, suggesting poor past performance.
• Repricing can be viewed negatively by shareholders as it dilutes the value of existing shares and rewards management despite underperformance.
• The original exercise prices of $5.00 and $6.50 were significantly higher than the new $1.38, highlighting a substantial drop in stock value.

Risks

• Shareholder dissatisfaction and potential governance concerns due to repricing options, especially if the company's performance has been poor.
• The significant drop in stock price from original option grant prices ($5.00, $6.50) to the current $1.38 suggests underlying business challenges or market perception issues.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the expiration dates of the options. The repricing itself implies a future expectation that the stock price will exceed $1.38, thereby restoring incentive value for the CEO.

Management Comments

• The board of directors of the Company approved to reprice the options from its previous exercise price of $5.00 to $1.38. All of the other terms of the option remain unchanged.
• The board of directors of the Company approved to reprice the options from its previous exercise price of $6.50 to $1.38. All of the other terms of the option remain unchanged.
• The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on September 15, 2025.

Industry Context

Option repricing is a controversial practice, typically seen in companies whose stock price has significantly underperformed. It aims to restore the incentive value of options for executives but can be viewed negatively by shareholders as it effectively rewards management for past failures. In the pharmaceutical industry, stock volatility can be high due to clinical trial results, regulatory approvals, and market competition, which might lead to such actions during downturns.

Comparison to Industry Standards

• Option repricing is generally considered a poor corporate governance practice by institutional investors and proxy advisory firms (e.g., ISS, Glass Lewis) unless specific, compelling circumstances and shareholder approval are present.
• Many companies, especially those with strong governance, avoid repricing options due to the negative perception and potential for shareholder backlash.
• Compared to companies that maintain strict equity compensation policies, MIRA's decision to reprice options for its CEO suggests a less stringent approach to executive incentives or a critical need to re-motivate leadership amidst significant stock price decline.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact due to perceived dilution and rewarding management for underperformance; potential positive if repricing re-motivates management leading to future stock appreciation.
• Management (Erez Aminov): Significant positive impact as options become 'in-the-money' or closer to it, restoring incentive value.
• Employees: No direct impact mentioned, but could affect morale if perceived as unfair executive treatment.

Key Dates

Recommendation

The repricing of the CEO's stock options from significantly higher prices ($5.00 and $6.50) to $1.38 strongly suggests substantial past stock underperformance. While this action aims to re-incentivize management, it raises corporate governance concerns and could be viewed negatively by shareholders. However, a re-motivated CEO with 'in-the-money' options might drive future value. Given the mixed signals of past underperformance and renewed executive incentive, a 'hold' recommendation is appropriate to monitor the company's strategic execution and stock performance post-repricing.

Keywords

MIRA Pharmaceuticals, MIRA, SEC Form 4, Stock Options, Option Repricing, Erez Aminov, CEO, Executive Compensation, Corporate Governance, Beneficial Ownership